ArticleRSC advances2025
Green synthesized mesoporous silica nanoparticles offer a promising drug delivery system investigated in physiologically relevant 3D microfluidic models.
Article in RSC advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Dual-source mesoporous nanosilicas from horsetail plant and chemical precursors show structural and textural evidence for vitamin C loading and release.Scientific reports · 2026Article
- Sustained release of Eugenol from MCM-41 mesoporous silica for preservation ofFood chemistry: X · 2026Article
- Replicating the post-chemotherapy tumor microenvironmentRSC advances · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mesoporous silica nanoparticles (MSNs) are attractive drug delivery carriers, and green synthesis from biowaste offers an eco-friendly alternative to conventional methods. Unlike previous studies limited to a single precursor, this work systematically compares multiple biosources, including rice husk (RH), wheat husk (WH), wheat stalk (WS), oat husk (OH), oat stalk (OS), and horsetail (HT), and establishes a standardized route to evaluate precursor influence. Among the tested precursors, RH and HT produced the highest purity silica and were selected for MSN synthesis. The resulting MSNs showed well-defined mesoporosity, high surface area, and controlled pore sizes, confirmed by FTIR, XRD, BET, and HR-TEM with pH-responsive Dox release enhanced under acidic conditions. They were biocompatible with HDFs, HUVECs, and U87 cells, while Dox-loaded MSNs exhibited strong anticancer effects against U87 cells at low drug concentration. The second novelty lies in evaluating MSN cellular uptake under physiologically relevant conditions using a microfluidic platform that mimics blood circulation, in contrast to conventional static assays. Cellular uptake was analyzed in 2D cultures and 3D microfluidic models, incorporating both static and dynamic conditions using HUVECs and U87. Notably, the dynamic 3D model, which simulates blood circulation, significantly enhanced MSN uptake by HUVECs and U87 compared to static conditions. These results emphasize the importance of physiological flow in optimizing nanoparticle-based drug delivery. This study introduces a dual innovation by establishing a consistent, multi-biosource approach for green MSN synthesis and validating their drug delivery potential in a realistic dynamic microenvironment, bridging sustainable nanomaterial development with advanced preclinical testing.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.